GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Preferred Dividends

MedMira (MedMira) Preferred Dividends : $0.00 Mil (TTM As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. MedMira's preferred dividends for the three months ended in Jan. 2024 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Jan. 2024 was $0.00 Mil.


MedMira Preferred Dividends Historical Data

The historical data trend for MedMira's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Preferred Dividends Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Preferred Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MedMira Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.


MedMira  (OTCPK:MMIRF) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports First Quarter Results FY2021

By GlobeNewswire GlobeNewswire 12-25-2020

MedMira Announces Product Update

By GlobeNewswire GlobeNewswire 12-31-2020

MedMira Reports First Quarter Results FY2022

By GlobeNewswire GlobeNewswire 12-31-2021

MedMira Reports Third Quarter Results FY2021

By GlobeNewswire GlobeNewswire 06-30-2021

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 12-01-2021

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018